Acta Medica Okayama JUNE2008. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Ikuko Miyazaki Masato Asanuma
|
|
- Katrina Rice
- 5 years ago
- Views:
Transcription
1 Acta Medica Okayama Volume 62, Issue Article 1 JUNE2008 Dopaminergic neuron-specific oxidative stress caused by dopamine itself Ikuko Miyazaki Masato Asanuma Department of Brain Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, miyazaki@cc.okayama-u.ac.jp Department of Brain Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Copyright c 1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved.
2 Dopaminergic neuron-specific oxidative stress caused by dopamine itself Ikuko Miyazaki and Masato Asanuma Abstract Oxidative stress, including the reactive oxygen or nitrogen species generated in the enzymatical oxidationor auto-oxidation of an excess amount of dopamine, is thought to play an important role in dopaminergic neurotoxicity. Dopamine and its metabolites containing 2 hydroxyl residues exert cytotoxicityin dopaminergic neuronal cells, primarily due to the generation of highly reactive dopamine and DOPA quinones. Dopamine and DOPA quinones may irreversibly alter protein function through the formation of 5-cysteinyl-catechols on the proteins. Furthermore, the quinone formation is closely linked to other representative hypotheses such as mitochondrial dysfunction, inflammation, oxidative stress, and dysfunction of the ubiquitin-proteasome system, in the pathogenesis of neurodegenerative diseases. Therefore, pathogenic effects of the dopamine quinone have recently focused on dopaminergicneuron-specific oxidative stress. In this article, we primarily review recent studies on the pathogenicity of quinone formation, in addition to several neuroprotective approaches against dopaminequinone-induced dysfunction of dopaminergic neurons. KEYWORDS: dopamine quinone, quinoprotein, methamphetamine, Parkinson?s disease, L-DOPA Copyright c 1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL. All rights reserved PMID:
3 Miyazaki and Asanuma: Dopaminergic neuron-specific oxidative stress caused by dopamine Dopaminergic Neuron-Specific Oxidative Stress Caused by Dopamine Itself * ʼ ʼ Produced by The Berkeley Electronic Press,
4 Acta Medica Okayama, Vol. 62 [2008], Iss. 3, Art. 1 ʼ ʼ 2
5 Miyazaki and Asanuma: Dopaminergic neuron-specific oxidative stress caused by dopamine ʼ ʼ ʼ,,,,, Produced by The Berkeley Electronic Press,
6 Acta Medica Okayama, Vol. 62 [2008], Iss. 3, Art. 1 ʼ 4
7 Miyazaki and Asanuma: Dopaminergic neuron-specific oxidative stress caused by dopamine ʼ ʼ ʼ ʼ ʼ Produced by The Berkeley Electronic Press,
8 Acta Medica Okayama, Vol. 62 [2008], Iss. 3, Art. 1 ʼ 6
9 Miyazaki and Asanuma: Dopaminergic neuron-specific oxidative stress caused by dopamine ʼ ʼ ʼ Produced by The Berkeley Electronic Press,
10 Acta Medica Okayama, Vol. 62 [2008], Iss. 3, Art ʼ ʼ ʼ ʼ ʼ ʻ ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ
11 Miyazaki and Asanuma: Dopaminergic neuron-specific oxidative stress caused by dopamine ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ Produced by The Berkeley Electronic Press,
12 Acta Medica Okayama, Vol. 62 [2008], Iss. 3, Art ʼ
Acta Medica Okayama. Jichun Wang Hiroyuki Matsuoka Makoto Hirai Ling Mu Liandi Yang Enjie Luo
Acta Medica Okayama Volume 64, Issue 1 2010 Article 7 FEBRUARY 2010 The First Case of a Class I Glucose-6-phosphate Dehydrogenase Deficiency, G6PD Santiago de Cuba (1339 GA), in a Chinese Population as
More informationActa Medica Okayama. Initial Report of Hybrid Radical Prostatectomy for Prostate Cancer:Reduced Bleeding, Clear Vision, and Secure Surgical Margins
Acta Medica Okayama Volume 62, Issue 6 2008 Article 4 DECEMBER 2008 Initial Report of Hybrid Radical Prostatectomy for Prostate Cancer:Reduced Bleeding, Clear Vision, and Secure Surgical Margins Takashi
More informationActa Medica Okayama. Differential, histochemical and immunohistochemical changes in rat hepatocytes after isoflurane or sevoflurane exposure.
Acta Medica Okayama Volume 57, Issue 1 2003 Article 1 FEBRUARY 2003 Differential, histochemical and immunohistochemical changes in rat hepatocytes after isoflurane or sevoflurane exposure. Mayumi Honda
More informationActa Medica Okayama APRIL 2001
Acta Medica Okayama Volume 55, Issue 2 2001 Article 7 APRIL 2001 Comparison of chromosome aberrations in peripheral blood lymphocytes from people occupationally exposed to ionizing and radiofrequency radiation.
More informationActa Medica Okayama. A comparison of the signal pathways between the TNF alpha- and oridonin-induced murine L929 fibrosarcoma cell death.
Acta Medica Okayama Volume 59, Issue 6 2005 Article 4 DECEMBER 2005 A comparison of the signal pathways between the TNF alpha- and oridonin-induced murine L929 fibrosarcoma cell death. Jian Huang Lijun
More informationActa Medica Okayama. Preoperative multidisciplinary treatment with hyperthermia for soft tissue sarcoma APRIL Volume 51, Issue Article 6
Acta Medica Okayama Volume 51, Issue 2 1997 Article 6 APRIL 1997 Preoperative multidisciplinary treatment with hyperthermia for soft tissue sarcoma Eiichi Makihata, Okayama University Masahiro Kuroda,
More informationActa Medica Okayama AUGUST A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections.
Acta Medica Okayama Volume 58, Issue 4 2004 Article 1 AUGUST 2004 A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections. Keiji Iwatsuki Takenobu Yamamoto
More informationActa Medica Okayama OCTOBER Mastectomy in Female-to-male Transsexuals. Yuzaburo Namba Toshiyuki Watanabe Yoshihiro Kimata
Acta Medica Okayama Volume 63, Issue 5 2009 Article 4 OCTOBER 2009 Mastectomy in Female-to-male Transsexuals Yuzaburo Namba Toshiyuki Watanabe Yoshihiro Kimata Department of Plastic and Reconstructive
More informationActa Medica Okayama. Differentiation of thyroid nodules using Tl-201 scintigraphy quantitative analysis and fine-needle aspiration biopsy.
Acta Medica Okayama Volume 58, Issue 2 2004 Article 3 APRIL 2004 Differentiation of thyroid nodules using Tl-201 scintigraphy quantitative analysis and fine-needle aspiration biopsy. Yasuhiro Yamamoto,
More informationActa Medica Okayama. Abscess Formation of the Round Ligament of the Liver: Report of a Case
Acta Medica Okayama Volume 62, Issue 6 2008 Article 8 DECEMBER 2008 Abscess Formation of the Round Ligament of the Liver: Report of a Case Kazunori Tsukuda Shiro Furutani Saki Nakahara Akihiro Tada Keitaro
More informationActa Medica Okayama. Pathophysiological functions of CD30+ CD4+ T cells in rheumatoid arthritis. DECEMBER Volume 57, Issue Article 1
Acta Medica Okayama Volume 57, Issue 6 2003 Article 1 DECEMBER 2003 Pathophysiological functions of CD30+ CD4+ T cells in rheumatoid arthritis. Akira Okamoto Masahiro Yamamura Mitsuhiro Iwahashi Tetsushi
More informationActa Medica Okayama. Metastatic carcinoma of the colon similar to Crohn s disease: a case report. AUGUST Volume 58, Issue Article 7
Acta Medica Okayama Volume 58, Issue 4 2004 Article 7 AUGUST 2004 Metastatic carcinoma of the colon similar to Crohn s disease: a case report. Kohji Tanakaya Hitoshi Takeuchi Yoshimasa yasui Akira Takeda
More informationActa Medica Okayama. Sneddon s syndrome: clinical and laboratory analysis of 10 cases. APRIL Volume 58, Issue Article 1
Acta Medica Okayama Volume 58, Issue 2 2004 Article 1 APRIL 2004 Sneddon s syndrome: clinical and laboratory analysis of 10 cases. Ertugrul Bolayir Abdulkerim Yilmaz Nesim Kugu Haydar Erdogan Melih Akyol
More informationAbstracts and affiliations
Dopamine Discovery Day August 30, 2012 Rikshospitalet Store auditorium, Oslo, Norway Organized by Linda H. Bergersen & Vidar Gundersen Institute of Basic Medical Sciences & Centre for Molecular Biology
More informationThe Role of DOPAL in Parkinson s Disease. Karenee Demery. Copyright May, 2015, Karenee Demery and Koni Stone
The Role of DOPAL in Parkinson s Disease Karenee Demery Copyright May, 2015, Karenee Demery and Koni Stone Parkinson s disease is an incurable, neurodegenerative disease. The cause is still not fully understood.
More information3 O Methyldopa inhibits astrocyte mediated dopaminergic neuroprotective effects of l DOPA
DOI 10.1186/s12868-016-0289-0 BMC Neuroscience RESEARCH ARTICLE Open Access 3 O Methyldopa inhibits astrocyte mediated dopaminergic neuroprotective effects of l DOPA Masato Asanuma 1,2* and Ikuko Miyazaki
More informationActa Medica Okayama APRIL 1963
Acta Medica Okayama Volume 17, Issue 2 1963 Article 4 APRIL 1963 Influence of local pressure on athetoid, electro-myogram of spastic paraplegia in water, and influence of oxygen inhalation on the tone
More information475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)
475 GERIATRIC PSYCHOPHARMACOLOGY (p.1) I. General Information? Use lower doses? Start low and go slow? Expect prolonged elimination ½ lives? Expect sedative-hypnotics to be dementing, to impair cognitive
More informationActa Medica Okayama. Catastrophic secondary antiphospholipid syndrome with peripheral nervous system involvement: a case report.
Acta Medica Okayama Volume 58, Issue 2 2004 Article 7 APRIL 2004 Catastrophic secondary antiphospholipid syndrome with peripheral nervous system involvement: a case report. Nilgun Erten Bulent Saka M Akif
More informationE. Haritov, E. Angeleska and N. Boyadjieva Department of pharmacology and toxicology, Medical Faculty, Medical University So a
:.,..,, KETOGENIC DIET AND EPILEPSY: THE ROLE OF KETONE BODIES IN THE INFLUENCE N NEURONAL EXCITABILITY E. Haritov, E. Angeleska and N. Boyadjieva Department of pharmacology and toxicology, Medical Faculty,
More informationNovel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson s disease
Baranyi et al. Molecular Neurodegeneration (2016) 11:6 DOI 10.1186/s13024-015-0067-y RESEARCH ARTICLE Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson
More informationIntegrative approaches to Parkinson s Disease
Integrative approaches to Parkinson s Disease Brian Harris Kopell, M.D. C0-Director, Center for Neuromodulation Associate Professor Departments of Neurosurgery, Neurology, Psychiatry and Neuroscience An
More informationMovement Disorders: A Brief Overview
Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance
More informationSummary and Conclusion
Parkinson s disease is a progressive disorder of the nervous system primarily affecting the motor system of the body and is also known as Shaking palsy (Bendick, 2002). Parkinson's disease is the second
More informationActa Medica Okayama AUGUST Normal chemotactic activity of granulocytes obtained by filtration leucapheresis
Acta Medica Okayama Volume 31, Issue 4 1977 Article 7 AUGUST 1977 Normal chemotactic activity of granulocytes obtained by filtration leucapheresis Hironobu Toki Koichi Kitajima Isao Takahashi Masaaki Tokioka
More informationNeurodegenerative Disease. April 12, Cunningham. Department of Neurosciences
Neurodegenerative Disease April 12, 2017 Cunningham Department of Neurosciences NEURODEGENERATIVE DISEASE Any of a group of hereditary and sporadic conditions characterized by progressive dysfunction,
More informationActa Medica Okayama JUNE 2009
Acta Medica Okayama Volume 63, Issue 3 29 Article 1 JUNE 29 Radiographic Prediction of the Results of Long-term Treatment with the Pavlik Harness for Developmental Dislocation of the Hip Takao Ohmori Hirosuke
More informationActa Medica Okayama. Masana Ogata FEBRUARY Volume 16, Issue Article 2. Okayama University,
Acta Medica Okayama Volume 16, Issue 1 1962 Article 2 FEBRUARY 1962 Studies on the protein synthesis in poisoning. III. Labeling of ph-5 enzyme with C14-glycine and the inhibition by para chloromercuribenzoate
More informationActa Medica Okayama. Studies on diagnosis of leukemia by tissue culture. Kiyoshi Hiraki APRIL Volume 12, Issue Article 8
Acta Medica Okayama Volume 12, Issue 1 1958 Article 8 APRIL 1958 Studies on diagnosis of leukemia by tissue culture Kiyoshi Hiraki Okayama University, Copyright c 1999 OKAYAMA UNIVERSITY MEDICAL SCHOOL.
More informationActa Medica Okayama JULY Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine
Acta Medica Okayama Volume 32, Issue 3 1978 Article 1 JULY 1978 Demonstration of enzymatic activity converting azathioprine to 6-mercaptopurine Akiharu Watanabe Norio Hobara Hideo Nagashima Okayama University,
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationThe Shaking Palsy of 1817
The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms
More informationmetabolism inhibition, this approach causes other adverse effects. The dosage of L-dopa can be brought down further by co-medication of dopamine
6XPPDU\ Parkinson s disease is a serious neurological disorder of the central nervous system that usually becomes apparent after the age of 55. It concerns the increased deterioration of neurons responsible
More informationCheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy
Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:
More informationOxidative Mechanisms and Tardive Dyskinesia
REVIEW ARTICLE CNS Drugs 2003; 17 (1): 47-62 1172-7047/03/0001-0047/$30.00/0 Adis International Limited. All rights reserved. Oxidative Mechanisms and Tardive Dyskinesia James B. Lohr, Ronald Kuczenski
More informationPHRM20001: Pharmacology - How Drugs Work!
PHRM20001: Pharmacology - How Drugs Work Drug: a chemical that affects physiological function in a specific way. Endogenous substances: hormones, neurotransmitters, antibodies, genes. Exogenous substances:
More informationMaking Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease
Making Every Little Bit Count: Parkinson s Disease SHP Neurobiology of Development and Disease Parkinson s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the
More informationActa Medica Okayama. Electron microscopic demonstration of a new virus isolated from a patient with SMON. Zensuke Ota DECEMBER 1970
Acta Medica Okayama Volume 24, Issue 6 1970 Article 3 DECEMBER 1970 Electron microscopic demonstration of a new virus isolated from a patient with SMON Zensuke Ota Okayama University, Copyright c 1999
More information01/11/2012. Neurological disorders and nutrition. Nutritional and related assessments. Non-nutritional causes: nutritional implications
Neurological disorders and nutrition General considerations, e.g., dysphagia Main topics and optional Canadian websites: STROKES www.heartandstroke.ca EPILEPSY www.epilepsy.ca PARKINSON S www.parkinson.ca
More informationPh D THESIS ABSTRACT
ALEXANDRU IOAN CUZA UNIVERSITY IAŞI FACULTY OF BIOLOGY THE STUDY OF CHANGES FOR SEVERAL BIOCHEMICAL PARAMETERS OF OXIDATIVE STRESS IN ANIMAL MODELS FOR NEUROPSYCHIATRIC DISORDERS Ph D THESIS ABSTRACT Scientific
More informationSuperoxide dismutase activity and zinc and copper concentrations in Parkinson s disease
Pathophysiology 7 (2000) 63 67 www.elsevier.com/locate/pathophys Superoxide dismutase activity and zinc and copper concentrations in Parkinson s disease Pelin Aribal Kocatürk a, *, M. Cenk Akbostanci b,
More informationActa Medica Okayama OCTOBER Decreased plasma postheparin lipolytic activity in systemic lupus erythematosus
Acta Medica Okayama Volume 31, Issue 5 1977 Article 4 OCTOBER 1977 Decreased plasma postheparin lipolytic activity in systemic lupus erythematosus Koichi Kawanishi Hidenori Ueda Masayuki Nagase Tadashi
More informationActa Medica Okayama. Takashi Seno FEBRUARY Volume 22, Issue Article 4. Okayama University,
Acta Medica Okayama Volume 22, Issue 1 1968 Article 4 FEBRUARY 1968 Protein concentration of synovial fluid in chronic rheumatoid arthritis. Estimation of protein in the synovial fluid of chronic rheumatoid
More informationDopamine metabolism. JOURNAL OF NEUROCHEMISTRY doi: /jnc.12686
JOURNAL OF NEUROCHEMISTRY 2014 129 898 915 doi: 10.1111/jnc.12686, *Faculty of Medicine, Molecular and Clinical Pharmacology, ICBM, University of Chile, Santiago, Chile Departamento de Ciencias Basicas,
More informationImpact of vitamins & nutrients on neurological function. B-vitamins and aging. Nafisa Jadavji, PhD
Impact of vitamins & nutrients on neurological function B-vitamins and aging Nafisa Jadavji, PhD nafisa.jadavji@carleton.ca Lecture Outline Answer to questions from last class Homocysteine Vitamin B9:
More informationDRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer
DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology
More informationModulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin
Pettit et al. Lipids in Health and Disease 213, 12:16 RESEARCH Open Access Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin Lauren K Pettit 1, Christopher
More informationActa Medica Okayama APRIL 1974
Acta Medica Okayama Volume 28, Issue 2 1974 Article 4 APRIL 1974 Carcinogenesis in tissue culture. 22. Malignant transformation of cloned rat liver cells treated in culture with 4-dimethylaminoazobenzene
More informationPharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology
+ Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning
More informationFollow this and additional works at: Part of the Medicinal Chemistry and Pharmaceutics Commons
Wayne State University Wayne State University Dissertations 1-1-2013 Design, Synthesis, Biological Evaluation And Molecular Modeling Studies Of Novel Multifunctional Neuroprotective Drugs For The Treatment
More informationModeling Parkinson s disease: systems to test gene-environment interactions
Modeling Parkinson s disease: systems to test gene-environment interactions Jason Cannon, Ph.D. Pittsburgh Institute of Neurodegenerative Diseases University of Pittsburgh Outline Parkinson s disease (PD)
More informationTargeting the Progression of Parkinson s Disease
Targeting the Progression of Parkinson s Disease Current Neuropharmacology, 2009, 7, 9-36 9 J.L. George 1, S. Mok 1, D. Moses 2, S. Wilkins 1, A.I. Bush 1, R.A. Cherny 1 and D.I. Finkelstein 1,* 1 The
More informationNEUROPLASTICITY IN THE NIGROSTRIATAL SYSTEM OF MPTP-TREATED MICE AT THE PRESYMPTOMATIC AND EARLY SYMPTOMATIC STAGES OF PARKINSONISM
NEUROPLASTICITY IN E NIGROSTRIATAL SYSTEM OF MPTP-TREATED MICE AT E PRESYMPTOMATIC AND EARLY SYMPTOMATIC STAGES OF PARKINSONISM Michael V. Ugrumov Institute of Developmental Biology RAS, Moscow, Russia
More informationEvaluations & CE. With Support From. Featured Speaker 1/20/2016. Conflict of Interest & Disclosure Statements
With Support From University at Albany School of Public Health New York State Department of Health New York State Association of County Health Officials (NYSACHO) Parkinson s Disease: The Importance of
More informationAnalysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease
Oxidative Stress laboratory Analysis of volatile organic compounds in rats with dopaminergic lesion: possible application for early detection of Parkinson s disease By Dr. Soliman Khatib Senior lecturer,
More informationP. Riederer, D. B. CaIne, R. Horowski, Y. Mizuno, W. Poewe, M. B. H. Youdim (eds.) Advances in Research on N eurodegeneration.
P. Riederer, D. B. CaIne, R. Horowski, Y. Mizuno, W. Poewe, M. B. H. Youdim (eds.) Advances in Research on N eurodegeneration Volume 5 Springer WienN ewyork Prof. Dr. P. Riederer Department of Psychiatry,
More informationScott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE LEARNING OBJECTIVES The Course Participant will: 1. Be familiar with the pathogenesis of Parkinson s Disease (PD) 2. Understand clinical
More informationParkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai
Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there
More informationMalattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche
LA NEUROSONOLOGIA NELLE PATOLOGIE DEGENERATIVE E VASCOLARI CEREBRALI San Benedetto del Tronto 6-8 novembre 2017 Malattia di Parkinson: patogenesi molecolare e nuove strategie terapeutiche Giuseppe De Michele
More informationBee venom acupuncture in different neurological illness and its immune modulation ACKNOWLEDGMENTS
Bee venom acupuncture in different neurological illness and its immune modulation ACKNOWLEDGMENTS MONA MOSTAFA FARID 1 Introduction 2 Bee venom have been widely used in Oriental medicine to relieve pain
More informationAdverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology
Adverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology Marcel Leist In Vitro Toxicology and Biomedicine Doerenkamp-Zbinden Chair, University of Konstanz, Germany
More informationPresented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn
Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for
More informationTreatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS
Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS
More informationActa Medica Okayama OCTOBER 1958
Acta Medica Okayama Volume 12, Issue 3 1958 Article 4 OCTOBER 1958 A histochemical study of the red and white muscle fibers Part I. Activity of the succinoxydase system in muscle fibers Takuro Ogata Okayama
More informationCHAPTER 1 INTRODUCTION
CAPTER 1 ITRDUCTI 1.1 GEERAL BACKGRUD In 1817, James Parkinson wrote a monograph Essay on the Shaking Palsy, in which he described six patients who had involuntary tremulous movements, whose muscles were
More informationMechanistic Toxicology
SECOND EDITION Mechanistic Toxicology The Molecular Basis of How Chemicals Disrupt Biological Targets URS A. BOELSTERLI CRC Press Tavlor & France Croup CRC Press is an imp^t o* :H Taylor H Francn C'r,,jpi
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
MOLECULAR DOCKING OF QUERCETIN, HESPERIDIN AND L-DOPA WITH MITOCHONDRIAL PROTEINS RELATED TO PARKINSON S DISEASE SRIMATHI PRIYANGA. K 1, VIJAYALAKSHMI. K 2 1. Research scholar, Department of biochemistry,
More informationWelcome and Introductions
Parkinson s Disease Spotlight on Treatment Advances Tuesday, January 26, 2016 Welcome and Introductions Stephanie Paul Vice President Development and Marketing American Parkinson Disease Association 1
More informationConversionofaminoacidsto specializedproducts
Conversionofaminoacidsto specializedproducts α-nitrogen atom of amino acids is a primary source for many nitrogenous compounds: Heme Purines and pyrimidines Hormones Neurotransmitters Biologically active
More informationActa Medica Okayama. Studies on the Etiology of Glaucoma Part 4. On the Effector Organs in Eyeball. Goro Akagi JUNE 1957
Acta Medica Okayama Volume 11, Issue 2 1957 Article 3 JUNE 1957 Studies on the Etiology of Glaucoma Part 4. On the Effector Organs in Eyeball Goro Akagi Okayama University, Copyright c 1999 OKAYAMA UNIVERSITY
More informationANTIOXIDANT ACTIVITY OF β-carboline DERIVATIVES
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 68 No. 2 pp. 185ñ189, 2011 ISSN 0001-6837 Polish Pharmaceutical Society DRUG BIOCHEMISTRY ANTIOXIDANT ACTIVITY OF β-carboline DERIVATIVES RENATA FRANCIK
More informationTHE EFFECT OF L-TYROSINE, VITAMINS E AND C ON PERPHENAZINE-INDUCED CATATONIA IN RAT
Jundishapur Journal of Natural Pharmaceutical Products 7; (): 8- Jundishapur Journal of Natural Pharmaceutical Products THE EFFECT OF L-TYROSINE, VITAMINS E AND C ON PERPHENAZINE-INDUCED CATATONIA IN RAT
More informationRe-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.
Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed
More informationEdaravone: A Review on Analytical Method and its Determination in Biological Matrix and Synthetic Mixture
80 Review Article Edaravone: A Review on Analytical Method and its Determination in Biological Matrix and Synthetic Mixture Patel Divya A. 1 *, Raj Hasumati 1, Patel Roshni 2 1 Department of Quality Assurance,
More informationHYPERBARIC OXYGEN TREATMENT ON A PARKINSON S DISEASE PATIENT: A CASE STUDY Hoggard ML, Johnson KE and Shirachi DY. Chico Hyperbaric Center, Chico, CA
HYPERBARIC OXYGEN TREATMENT ON A PARKINSON S DISEASE PATIENT: A CASE STUDY Hoggard ML, Johnson KE and Shirachi DY. Chico Hyperbaric Center, Chico, CA 95926 and Department of Physiology and Pharmacology,
More informationNeuroprotective properties of GLP-1 - a brief overview. Michael Gejl Jensen, MD Dept. Of Pharmacology, AU
Neuroprotective properties of GLP-1 - a brief overview Michael Gejl Jensen, MD Dept. Of Pharmacology, AU mg@farm.au.dk Agenda Glucagon-like peptide (GLP-1) GLP-1 and neuronal activity GLP-1 in disease-specific
More informationThis student paper was written as an assignment in the graduate course
77:222 Spring 2003 Free Radicals in Biology and Medicine Page 0 This student paper was written as an assignment in the graduate course Free Radicals in Biology and Medicine (77:222, Spring 2003) offered
More informationReactive dopamine metabolites and neurotoxicity : the role of GAPDH and pesticide exposure in Parkinson's disease pathology
University of Iowa Iowa Research Online Theses and Dissertations Spring 2016 Reactive dopamine metabolites and neurotoxicity : the role of GAPDH and pesticide exposure in Parkinson's disease pathology
More informationActa Medica Okayama. Malignant fibrous histiocytoma with skeletal involvement. Hideo Takechi Kohji Taguchi OCTOBER 1978
Acta Medica Okayama Volume 32, Issue 5 1978 Article 4 OCTOBER 1978 Malignant fibrous histiocytoma with skeletal involvement Hideo Takechi Kohji Taguchi Okayama University, Okayama University, Copyright
More informationThis dissertation is available at Iowa Research Online:
University of Iowa Iowa Research Online Theses and Dissertations 2012 Covalent modification and inhibition of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, an endogenously produced neurotoxin
More informationCDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease
CDNF: Finnish academia-industry collaboration for unique clinical study in Parkinson s disease Brain Diseases Symposium, Helsinki 14 Oct 2016 Pekka Simula, CEO, Herantis Pharma Plc 1 Disclaimer This presentation
More informationNeurodegenerative diseases
Neurodegenerative diseases Hiwa K. Saaed, PhD Department of Pharmacology & Toxicology College of Pharmacy University of Sulaimani Hiwa.saaed@univsul.edu.iq 2018-19 Neurodegenerative diseases of the CNS
More informationDISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
DISORDERS OF THE MOTOR SYSTEM Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine THE MOTOR SYSTEM To understand disorders of the motor system, we need to review how a
More informationBiochimica et Biophysica Acta
Biochimica et Biophysica Acta 1822 (212) 1125 1136 Contents lists available at SciVerse ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbadis verexpression of VMAT-2
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:10.1038/nature13418 Supplementary Results: USP30 opposes autophagic flux In HEK-293 cells, USP30 overexpression increased basal LC3-II levels, dependent on enzymatic activity,
More informationClasses of Neurotransmitters. Neurotransmitters
1 Drugs Outline 2 Neurotransmitters Agonists and Antagonists Cocaine & other dopamine agonists Alcohol & its effects / Marijuana & its effects Synthetic & Designer Drugs: Ecstasy 1 Classes of Neurotransmitters
More informationNicotine: Everything You Need to Know but Have Never Been Told
Bernd Mayer Pharmacology & Toxicology University of Graz, Austria Nicotine: Everything You Need to Know but Have Never Been Told Bernhard-Michael (Bernd) Mayer, PhD Professor & Chair Department of Pharmacology
More informationChapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.
Chapter 8 Parkinsonism M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University. Definition of Parkinson s Disease Parkinson's disease is a progressive, neurodegenerative disease
More informationImmunotherapy for the Treatment of Parkinson's Disease
University of Colorado, Boulder CU Scholar Undergraduate Honors Theses Honors Program Spring 2014 Immunotherapy for the Treatment of Parkinson's Disease Matthew Follett University of Colorado Boulder Follow
More informationLatest Research on the new Laser Watch
Latest Research on the new Laser Watch 1 Axel von Hirschheydt, MD Lauenfoerde/Germany 12th International Conference for Medical Laser Applications June 09/10 2017, Beverungen/Germany Research Network:
More informationIULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY DOCTORAL SCHOOL NEUROSCIENCE SECTION 6 28 MARCH UMF IULIU HATIEGANU CLUJ-NAPOCA ROMANIA
IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY DOCTORAL SCHOOL NEUROSCIENCE P R O G R A M 2016-2017 SECTION 6 28 MARCH UMF IULIU HATIEGANU CLUJ-NAPOCA ROMANIA 1 PhD NEUROSCIENCE PROGRAM COORDINATOR
More informationNeuropharmacology NOTES
Neuropharmacology NOTES Contents Topic Page # Lecture 1- Intro to Neurochemical Transmission & Neuromodulation 2 Lecture 2- Serotonin & Noradrenaline 7 Lecture 3- Acetylcholine & Dopamine 14 Lecture 4-
More informationHistory Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson
Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological
More informationDRUGS THAT ACT IN THE CNS
DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called
More informationCANNABIS AND NEUROLGICAL DISORDERS
CANNABIS AND NEUROLGICAL DISORDERS Neurodegenerative diseases and movement disorders, which are sometimes interlinked, are among the many conditions that cannabis and cannabinoids may be particularly well
More informationRetrotope, Inc. A Clinical Stage Pharmaceutical Company
Reinforcing the molecules of life Retrotope, Inc. A Clinical Stage Pharmaceutical Company Retrotope has created a proprietary drug platform to preserve and restore cellular health in degenerative diseases.
More informationTIGAR's promiscuity Bolaños, Juan P.
TIGAR's promiscuity Bolaños, Juan P. TIGAR [TP53 (tumour protein 53)-induced glycolysis and apoptosis regulator] is an important survival factor for cancer cells. The enzymatic activity supported by sequence
More information1. INTRODUCTION Parkinson's disease (PD)
1. INTRODUCTION Parkinson's disease (PD) is a pathological condition that has been known for centuries through early Greek scientific descriptions, traditional Indian texts and ancient Chinese sources.
More information11/13/18. MICROBIOME AND THE BRAIN: How your gut impacts wellbeing. Approach. Lessons from Venice. Session One. Sue Langley
MICROBIOME AND THE BRAIN: How your gut impacts wellbeing Session One Sue Langley 2018 2017 Langley Group IP Trust Approach Lessons from Venice 1 Lessons from Venice Agenda 2. Implications and research
More information